Pesarrodona et al., 2014 - Google Patents
Intracellular targeting of CD44+ cells with self-assembling, protein only nanoparticlesPesarrodona et al., 2014
View PDF- Document ID
- 18231463269261877885
- Author
- Pesarrodona M
- Ferrer-Miralles N
- Unzueta U
- Gener P
- Tatkiewicz W
- Abasolo I
- Ratera I
- Veciana J
- Schwartz Jr S
- Villaverde A
- Vazquez E
- Publication year
- Publication venue
- International journal of pharmaceutics
External Links
Snippet
CD44 is a multifunctional cell surface protein involved in proliferation and differentiation, angiogenesis and signaling. The expression of CD44 is up-regulated in several types of human tumors and particularly in cancer stem cells, representing an appealing target for …
- 102000004169 proteins and genes 0 title abstract description 93
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48238—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid
- A61K47/48246—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pesarrodona et al. | Intracellular targeting of CD44+ cells with self-assembling, protein only nanoparticles | |
| Anas et al. | Clathrin-mediated endocytosis of quantum dot− peptide conjugates in living cells | |
| Kopeček et al. | Smart self‐assembled hybrid hydrogel biomaterials | |
| Walther et al. | Quantum dot− carrier peptide conjugates suitable for imaging and delivery applications | |
| Neuhaus et al. | Reversible opening of the blood-brain barrier by claudin-5-binding variants of Clostridium perfringens enterotoxin's claudin-binding domain | |
| Zhang et al. | Enhanced cellular entry and efficacy of tat conjugates by rational design of the auxiliary segment | |
| Wang et al. | Protein polymer nanoparticles engineered as chaperones protect against apoptosis in human retinal pigment epithelial cells | |
| Zhao et al. | Tetrahedral DNA nanostructure promotes endothelial cell proliferation, migration, and angiogenesis via notch signaling pathway | |
| Karagiannis et al. | Rational design of a biomimetic cell penetrating peptide library | |
| Vazquez et al. | Protein nanodisk assembling and intracellular trafficking powered by an arginine-rich (R9) peptide | |
| Matsumoto et al. | Targeting of EGF‐displayed protein nanoparticles with anticancer drugs | |
| Kuo et al. | Targeted nuclear delivery using peptide-coated quantum dots | |
| Cheraghi et al. | Development of a targeted anti-HER2 scFv chimeric peptide for gene delivery into HER2-positive breast cancer cells | |
| Veneti et al. | RGD-targeted liposome binding and uptake on breast cancer cells is dependent on elastin linker secondary structure | |
| Serna et al. | Rational engineering of single-chain polypeptides into protein-only, BBB-targeted nanoparticles | |
| Sun et al. | Interaction between cell-penetrating peptides and acid-sensitive anionic oligopeptides as a model for the design of targeted drug carriers | |
| Biswas et al. | Polyethylene glycol-based protein nanocapsules for functional delivery of a differentiation transcription factor | |
| Yamada et al. | Chirality switching within an anionic cell-penetrating peptide inhibits translocation without affecting preferential entry | |
| Lv et al. | Design of integrin αvβ3 targeting self-assembled protein nanoparticles with RGD peptide | |
| Tjandra et al. | Identification of novel medulloblastoma cell-targeting peptides for use in selective chemotherapy drug delivery | |
| Aliyandi et al. | Effect of endothelial cell heterogeneity on nanoparticle uptake | |
| Luo et al. | Live‐cell imaging of octaarginine‐modified polymer dots via single particle tracking | |
| Weber et al. | Concentration-independent multivalent targeting of Cancer cells by genetically encoded Core-crosslinked elastin/Resilin-like polypeptide micelles | |
| Li et al. | Revealing the dynamic mechanism by which transferrin promotes the cellular uptake of HAIYPRH peptide-conjugated nanostructures by force tracing | |
| Pesarrodona et al. | Engineering a nanostructured nucleolin-binding peptide for intracellular drug delivery in triple-negative breast cancer stem cells |